Genetics Adviser is a digital health platform offering a customizable, evidence-based solution that improves patient engagement, streamlines workflows, and helps scale the delivery of precision genomic medicine. Our platform offers pre-test education and psychosocial support, digital consent, return of results, and long-term patient management.
GeneDx
Fabric Genomics, a GeneDx company, is democratizing genomics-driven precision medicine. The company provides institutions with end-to-end clinical sequencing solutions that include the Fabric Enterprise software platform, assay design and validation support and the clinical interpretation services needed to scale genetic testing. At the core of this platform is a suite of sophisticated AI algorithms and data knowledge systems that turn data into expert clinical insights. Headquartered in Oakland, California, Fabric Genomics supports clinical applications across a variety of use cases including rare disease, oncology, cardiovascular, neurological and women’s health. To learn more, visit fabricgenomics.com and follow us on X and LinkedIn.
Gene by Gene
Genetic Lab Services and Genetic Reporting Services – Gene by Gene is a leader in Next-Generation Sequencing (NGS) supporting Clinical Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES). With 20+ years genetic expertise we provide cost effective, fast turn around, accurate genetic testing supporting clinically actionable insights for precision medicine. Our reporting division, myDNA, provides, Hereditary Disease, Carrier Screening, Pharmacogenomics (PGx), and Nutrigenomics (NGx) reports. Our cutting-edge laboratory and highly trained team of experts, are committed to excellence in the field of genetic analysis. Our CAP, CLIA laboratory also holds accreditation from New York State Department of Health, California Department of Public Health, and AABB. We ensure rapid, quality results are delivered globally.
Fulgent Genetics
Fulgent is a technology-driven Biopharma services company boasting a robust portfolio of clinical diagnostic, research solutions and R&D capabilities. Our clinical diagnostic and BioPharma business units provide a wide array of services including molecular diagnostic testing, comprehensive NGS genetic testing, RNASeq, targeted DNA / RNA panels (FFPE, Liquid Biopsy, Heme), single cell and spatial analysis (10x Genomics), proteomics (Olink) and top-tier anatomic pathology laboratory services (Immunohistochemistry (IHC), RNAscope (ISH), Akoya, Flow Cytometry). These offerings are meticulously crafted to support biomarker development in immuno-Oncology research complemented with actionable diagnostic insights, ultimately enhancing the quality of patient care. With a dedicated focus on patient screening and enrollment testing, biomarker analysis, and companion diagnostics for clinical research, Pharma Clinical trials, and contract research, Fulgent’s BioPharma Services cater to the specific needs of the pharmaceutical industry. With facilities situated in the US, China, and Australia, our overarching mission is to revolutionize the genomic diagnostic landscape, positioning ourselves as a fully integrated precision medicine company poised to drive advancements in healthcare. Fulgent’s latest step forward to this commitment is approval for the largest CE-marked Clinical Exome gene panel for genetic testing, underscoring our dedication to meeting the highest standards of regulatory compliance & quality. | Through our diverse testing menu, Fulgent is focused on transforming patient care in oncology, anatomic pathology, infectious and rare diseases, and reproductive health. We believe that by providing a wide range of effective, flexible testing options in conjunction with best-in-class service and support, we can redefine the way medicine is managed for patients and clinicians alike.
DNAnexus
DNAnexus: Accelerating the Future of Human Genetics and Precision Medicine The advancement of human genetics hinges on our ability to navigate and interpret vast, complex datasets. As research pushes the boundaries of discovery, from single-gene disorders to population-scale genomics, the challenges of data management, analysis, and collaboration have grown exponentially. DNAnexus is at the forefront of this evolution, providing a secure, scalable, and collaborative cloud-based platform designed to meet the unique needs of the global life sciences community. We are on a journey to democratize how researchers and clinicians work with clinico-genomic data, transforming it into actionable discoveries that improve patient outcomes. Unifying Complex, Multi-Modal Data at Scale DNAnexus leads the way in the management and analysis of multi-omics data to accelerate breakthroughs in precision medicine. Our Precision Health Data Cloud empowers life science organizations to seamlessly integrate complex genomic, transcriptomic, proteomic, clinical, and real-world datasets. This unified approach provides a holistic view of human biology, enabling researchers to uncover novel insights into disease mechanisms, identify new therapeutic targets, and power the next wave of drug discovery and development. The platform is built to handle data at scale, providing the robust foundation necessary for everything from rare disease analysis to large-scale population health studies. Fostering Secure Collaboration and Innovation Scientific progress is a collaborative endeavor. The DNAnexus platform provides a secure and collaborative environment where data can be combined and analyzed, fostering innovation without compromising on security or compliance. We enable this through solutions like Trusted Research Environments (TREs), which provide regulatory-grade spaces for dynamic collaboration and efficient, compliant submissions. Our unwavering commitment to the highest security standards ensures that sensitive data, privacy, and intellectual property are protected, allowing your teams to focus on what matters most: accelerating scientific discovery. Harnessing AI-Powered Analytics for Actionable Insights Built upon this foundation of integrated data and security, DNAnexus offers robust, AI-driven analytics to unlock the full potential of your research. By leveraging advanced AI and machine learning tools, our platform helps you move beyond raw data to find meaningful patterns and actionable insights. This empowers your organization to speed the journey from research to patient impact, simplifying regulatory compliance and driving innovations that improve healthcare for all. Engage with DNAnexus at ASHG 2025 to explore how our pioneering data analysis and management solutions can empower your research and help translate genetic discoveries into the future of precision health.
Coriell Institute for Medical Research
For the past 72 years, in pursuit of preventing and curing diseases, Coriell scientists have conducted groundbreaking research in infectious diseases, genetic diseases, cancer, aging and personalized medicine. Coriell has also pioneered the generation of research-accelerating biomaterials through establishing and curating key biobanks that now contain some of the world’s most extensive collection of cell lines, DNA, and other biomaterials gathered and distributed for use by the international research community. Coriell holds one of the first two official cell banks recognized by the National Institutes of Health (NIH) in 1960. Coriell currently hosts biobanks for the following NIH institutes: NIGMS, NINDS, NHGRI, NEI, and NIA. In addition to its biobanks, Coriell researchers currently study aging, cancer, stem cells, epigenomics, pharmacogenomics and many more topics. Many projects, such as the longstanding Camden Opioid Research Initiative (CORI – funded by the state of NJ) and the newly launched Camden Cancer Research Center (CCRC), focus more broadly on the historically underserved city of Camden and Southern New Jersey. | Founded in 1953, the Coriell Institute for Medical Research is a nonprofit research institute dedicated to improving human health through biomedical research. Coriell scientists lead research in cancer biology, epigenetics, and the genomics of opioid use disorder. Coriell also hosts one of the world’s leading biobanks—comprising collections for the National Institutes of Health, disease foundations and private clients—and distributes biological samples and offers research and biobanking services to scientists around the globe. To facilitate drug discovery and disease study, the Institute also develops and distributes collections of induced pluripotent stem cells. For more information, visit Coriell.org
Complete Genomics
Complete Genomics is a pioneering life sciences company that provides novel, complete sequencing solutions, including sample/library preparation, lab automation, sequencing, and data analysis. The sequencing portfolio offers a full lineup of sequencers, ranging from low to high throughput capacities, all powered by its proprietary DNBSEQ technology. Over 10,900 publications have been based on DNBSEQ technology across a wide range of applications. Complete Genomics is the exclusive distributor for STOmics products, powered by Stereo-seq technology —the only spatial technology globally capable of accessing the whole transcriptome at true single-cell resolution. | Complete Genomics is a pioneering life sciences company offering innovative, comprehensive sequencing solutions, including sample/library preparation, lab automation, sequencing, and data analysis. Our sequencing portfolio features a full range of sequencers designed to meet low, medium, and high throughput needs, all powered by our proprietary DNBSEQ technology. To date, over 9,700 publications have utilized DNBSEQ technology across a broad spectrum of applications. As the exclusive distributor of STOmics products in North America, Complete Genomics provides access to Stereo-seq technology—the only spatial transcriptomics solution worldwide capable of exploring the entire transcriptome at true single-cell resolution. To learn more, visit https://www.completegenomics.com
Common Fund Data Ecosystem (CFDE)
The Knowledge Center (KC) integrates data and knowledge generated by ground-breaking research programs in the NIH Common Fund Data Ecosystem. Use the KC to see curated and precomputed analyses of data within and across Common Fund projects.
Broad Clinical Labs
Broad Clinical Labs (BCL) is a subsidiary of the Broad Institute that provides a range of research and clinical services – including CLIA licensed and CAP accredited genomic data generation and advanced genomic analysis – both for the Broad research community and for the rest of the world.